A2780 PTX(32) resistant cell line

The paclitaxel resistant A2780 PTX (32) cell line with collateral sensitivity to cisplatin (inverse resistance) has been developed by continuous growing of A2780 PTX (16) cell line (cat. no 160731) in 32 nM PTX concentration (for details see Fig. 1). The half maximal inhibitory concentration (IC50) for PTX is about thirty two times as high the IC50 for A2780, whereas for CDDP it is about ten times lower (for details see Tab. 1).

Contributors

Inventor Institute
Jolanta Szenajch ; Luiza Handschuh ; Aleksandra Świercz ; Michał Góralski ; Alicja Szabelska-Beręsewicz; Joanna Zyprych-Walczak ; Idzi Siatkowski Military Institute of Medicine – National Research Institute
Cat. #: 160732
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Gynaecologic cancer
Research Fields: Cancer;Drug development
Organism: Human
Tissue: Ovary
Model: Tumour line
Growth properties: Adherent
Cancer Types In Detail: Ovarian
Product description: The paclitaxel resistant A2780 PTX (32) cell line with collateral sensitivity to cisplatin (inverse resistance) has been developed by continuous growing of A2780 PTX (16) cell line (cat. no 160731) in 32 nM PTX concentration (for details see Fig. 1). The half maximal inhibitory concentration (IC50) for PTX is about thirty two times as high the IC50 for A2780, whereas for CDDP it is about ten times lower (for details see Tab. 1). PTX and CDDP are standard chemotherapeutic drugs used in the treatment of ovarian cancer and acquired resistance to them remains a major obstacle in therapy. The trend of developing the inverse resistance is dominant in clinical practice, therefore A2780 PTX (32) cell line with other sublines of the series (see Notes for details) can be used as a primary tool for deciphering the molecular and cellular mechanisms of drug resistance in ovarian cancer. This cell line was generated as part of a series of isogenic ovarian cancer lines with gradually changing inverse resistance to PTX (resistant) and CDDP (sensitive); see A2780 PTX (4) Cat no:160729, A2780 PTX (8) Cat no:160730, A2780 PTX (16) Cat no:160731, A2780 PTX (64) Cat no:160733, and A2780 PTX (128) Cat no:160734 for the others (see Tab. 1 and Fig. 2 for details). Transcriptomes of six sublines were sequenced and the mRNA dataset was deposited under Gene Expression Omnibus Accession No GSE159791.Patent number: 233178
Production details: Split sub-confluent cultures (70-80%) seeding at 4 x 1000 (tolerated range: 1 x 1000 to 1 x 10 0000) cells/cm2 using TrypLE ExpressTM, 5% CO2, 37oC. Culture cells without drug until they have been fully adhered (after 24 h).
Parental cell line: A2780
disease: Cancer
Format: Frozen
Shipping conditions: Dry ice
Growth medium: RPMI 1640 medium + 2mM L-alanine-L-glutamine (GlutaMAXTM) + 5% heat-inactivated Foetal Bovine Serum (FBS) , at 37?‚°C and 5% CO2. To keep the stability of resistance profile not using antibiotics and antimycotics is recommended. Cells should be cultured without PTX (up to 10 days) to avoid the resistance escalation. After this time the maintenance treatment with 32 nM PTX for one passage is recommended.
References:

Szenajch et al. 2020. Int. J. Mol. Sci. 21(23): 9218. PMID: 33287223

Images

View Gallery

Related Tools for Cell lines

Cat. # Tool Name
151425 TR146 Cell Line Key Info View Tool
151450 JIM3 Cell Line Key Info View Tool
151484 2fTGH Cell Line Key Info View Tool
151663 MEF PKCe KO KI Cell Line Key Info View Tool
151665 MEF PKCe KO Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.